Your browser doesn't support javascript.
loading
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
Huselton, Eric; Rettig, Michael P; Campbell, Kirsten; Cashen, Amanda F; DiPersio, John F; Gao, Feng; Jacoby, Meagan A; Pusic, Iskra; Romee, Rizwan; Schroeder, Mark A; Uy, Geoffrey L; Marcus, Stephen; Westervelt, Peter.
Afiliação
  • Huselton E; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States; University of Rochester Medical Center, Rochester, NY, United States.
  • Rettig MP; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • Campbell K; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • Cashen AF; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • DiPersio JF; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • Gao F; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, Saint Louis, MO, United States.
  • Jacoby MA; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • Pusic I; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • Romee R; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States; Division of Hematologic Malignancies, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
  • Schroeder MA; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • Uy GL; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States.
  • Marcus S; Cantex Pharmaceuticals, Weston, FL, United States.
  • Westervelt P; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, United States. Electronic address: pwestervelt@wustl.edu.
Leuk Res ; 110: 106713, 2021 11.
Article em En | MEDLINE | ID: mdl-34619434
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Síndromes Mielodisplásicas / Heparina / Leucemia Mieloide Aguda / Regulação Neoplásica da Expressão Gênica / Resistencia a Medicamentos Antineoplásicos / Metilação de DNA Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Síndromes Mielodisplásicas / Heparina / Leucemia Mieloide Aguda / Regulação Neoplásica da Expressão Gênica / Resistencia a Medicamentos Antineoplásicos / Metilação de DNA Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido